BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375:2154-64. [PMID: 27717299 DOI: 10.1056/NEJMoa1611310] [Cited by in Crossref: 1016] [Cited by in F6Publishing: 462] [Article Influence: 203.2] [Reference Citation Analysis]
Number Citing Articles
1 Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis? Ann Transl Med 2020;8:1706. [PMID: 33490218 DOI: 10.21037/atm.2020.03.156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
3 Hollis RL, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat Commun 2020;11:4995. [PMID: 33020491 DOI: 10.1038/s41467-020-18819-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
4 van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs 2017;35:751-65. [PMID: 28303528 DOI: 10.1007/s10637-017-0451-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
5 Smith HL, Prendergast L, Curtin NJ. Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells. Cancers (Basel) 2020;12:E878. [PMID: 32260355 DOI: 10.3390/cancers12040878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Kiselev VI, Ashrafyan LA, Muyzhnek EL, Gerfanova EV, Antonova IB, Aleshikova OI, Sarkar FH. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer 2018;18:904. [PMID: 30236079 DOI: 10.1186/s12885-018-4792-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
7 Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D, Oberg HH, Pecks U, van Mackelenbergh M, Weimer J, Arnold N, Maass N, Bauerschlag DO. ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget 2018;9:16043-58. [PMID: 29662625 DOI: 10.18632/oncotarget.24682] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
8 Pan Z, Xie X. BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget 2017;8:97657-70. [PMID: 29228641 DOI: 10.18632/oncotarget.18280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
9 Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. Int J Mol Sci 2019;20:E3100. [PMID: 31242618 DOI: 10.3390/ijms20123100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
10 Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. Breast Cancer Res 2020;22:79. [PMID: 32711554 DOI: 10.1186/s13058-020-01313-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ueki A, Hirasawa A. Molecular Features and Clinical Management of Hereditary Gynecological Cancers. Int J Mol Sci 2020;21:E9504. [PMID: 33327492 DOI: 10.3390/ijms21249504] [Reference Citation Analysis]
12 Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K. Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opin Emerg Drugs 2019;24:239-53. [PMID: 31755325 DOI: 10.1080/14728214.2019.1696773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Murthy P, Muggia F. Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. Ecancermedicalscience 2019;13:904. [PMID: 30915162 DOI: 10.3332/ecancer.2019.904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Gong G, Lin T, Yuan Y. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. J Ovarian Res 2020;13:30. [PMID: 32192517 DOI: 10.1186/s13048-020-00632-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Göbel A, Zinna VM, Dell'Endice S, Jaschke N, Kuhlmann JD, Wimberger P, Rachner TD. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. BMC Cancer 2020;20:703. [PMID: 32727400 DOI: 10.1186/s12885-020-07164-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L. Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. Cancer Manag Res 2021;13:3081-100. [PMID: 33854378 DOI: 10.2147/CMAR.S292992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Haynes B, Murai J, Lee JM. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev 2018;71:1-7. [PMID: 30269007 DOI: 10.1016/j.ctrv.2018.09.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 15.3] [Reference Citation Analysis]
18 Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs 2020;80:131-46. [PMID: 31823331 DOI: 10.1007/s40265-019-01235-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
19 Pellegrino B, Musolino A, Llop-Guevara A, Serra V, De Silva P, Hlavata Z, Sangiolo D, Willard-Gallo K, Solinas C. Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Transl Oncol 2020;13:410-22. [PMID: 31901781 DOI: 10.1016/j.tranon.2019.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
20 Dharmaratne NU, Kaplan AR, Glazer PM. Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. Cells 2021;10:541. [PMID: 33806273 DOI: 10.3390/cells10030541] [Reference Citation Analysis]
21 Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949-61. [PMID: 28916367 DOI: 10.1016/S0140-6736(17)32440-6] [Cited by in Crossref: 596] [Cited by in F6Publishing: 279] [Article Influence: 149.0] [Reference Citation Analysis]
22 Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA. High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget 2017;8:104430-43. [PMID: 29262651 DOI: 10.18632/oncotarget.22303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer 2021;2:598-610. [PMID: 34179826 DOI: 10.1038/s43018-021-00203-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
24 Huang XZ, Jia H, Xiao Q, Li RZ, Wang XS, Yin HY, Zhou X. Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. Front Oncol 2020;10:958. [PMID: 32612955 DOI: 10.3389/fonc.2020.00958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Milanesio MC, Giordano S, Valabrega G. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers (Basel) 2020;12:E1315. [PMID: 32455819 DOI: 10.3390/cancers12051315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Kaltofen T, Preinfalk V, Schwertler S, Fraungruber P, Heidegger H, Vilsmaier T, Vattai A, Czogalla B, Mayr D, Mahner S, Jeschke U, Trillsch F. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. J Cancer Res Clin Oncol 2020;146:2559-74. [PMID: 32681294 DOI: 10.1007/s00432-020-03317-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Rosenbaum E, Jonsson P, Seier K, Qin LX, Chi P, Dickson M, Gounder M, Kelly C, Keohan ML, Nacev B, Donoghue MTA, Chiang S, Singer S, Ladanyi M, Antonescu CR, Hensley ML, Movva S, D'Angelo SP, Tap WD. Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precis Oncol 2020;4:PO. [PMID: 33283135 DOI: 10.1200/PO.20.00122] [Reference Citation Analysis]
28 McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. Int J Mol Sci 2020;21:E4272. [PMID: 32560059 DOI: 10.3390/ijms21124272] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
29 Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Target Oncol 2021;16:59-68. [PMID: 33369704 DOI: 10.1007/s11523-020-00780-4] [Reference Citation Analysis]
30 Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer 2020;8:e000375. [PMID: 32461346 DOI: 10.1136/jitc-2019-000375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
31 Cheng H, Yang J, Liu H, Xiang Y. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2021;304:285-96. [PMID: 34021367 DOI: 10.1007/s00404-021-06070-2] [Reference Citation Analysis]
32 van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG. The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. Cancers (Basel) 2020;12:E2805. [PMID: 33003546 DOI: 10.3390/cancers12102805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 2017;9:253-67. [PMID: 28491146 DOI: 10.1177/1758834016687254] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 13.8] [Reference Citation Analysis]
34 Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E. The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. Int J Mol Sci 2017;18:E210. [PMID: 28117679 DOI: 10.3390/ijms18010210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
35 Jönsson JM, Bååth M, Björnheden I, Sahin ID, Måsbäck A, Hedenfalk I. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer. Cancers (Basel) 2021;13:E254. [PMID: 33445465 DOI: 10.3390/cancers13020254] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol 2021;161:512-5. [PMID: 33610319 DOI: 10.1016/j.ygyno.2021.01.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Gupta M, Iyer R, Fountzilas C. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers (Basel) 2019;11:E1980. [PMID: 31835379 DOI: 10.3390/cancers11121980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
38 Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. Int J Biol Sci 2019;15:962-72. [PMID: 31182917 DOI: 10.7150/ijbs.30721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
39 Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 2018;81:17-38. [PMID: 29249039 DOI: 10.1007/s00280-017-3501-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 146] [Article Influence: 44.3] [Reference Citation Analysis]
40 Li P, Zhen Y, Yu Y. Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry. Methods Enzymol 2019;626:301-21. [PMID: 31606080 DOI: 10.1016/bs.mie.2019.06.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K. Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Transl Oncol 2019;12:1386-94. [PMID: 31382135 DOI: 10.1016/j.tranon.2019.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Hyman DM, Taylor BS, Baselga J. Implementing Genome-Driven Oncology. Cell. 2017;168:584-599. [PMID: 28187282 DOI: 10.1016/j.cell.2016.12.015] [Cited by in Crossref: 269] [Cited by in F6Publishing: 201] [Article Influence: 67.3] [Reference Citation Analysis]
43 Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE. PARP-1 regulates DNA repair factor availability. EMBO Mol Med 2018;10:e8816. [PMID: 30467127 DOI: 10.15252/emmm.201708816] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
44 Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer: focus on rucaparib. Int J Womens Health 2017;9:913-24. [PMID: 29290694 DOI: 10.2147/IJWH.S151194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
45 Hatano Y, Tamada M, Asano N, Hayasaki Y, Tomita H, Morishige KI, Hara A. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. Diagn Pathol 2019;14:4. [PMID: 30636633 DOI: 10.1186/s13000-019-0781-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol 2020;8:564601. [PMID: 33015058 DOI: 10.3389/fcell.2020.564601] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 29.0] [Reference Citation Analysis]
47 Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med 2019;381:1929-39. [PMID: 31722153 DOI: 10.1056/NEJMoa1902626] [Cited by in Crossref: 79] [Cited by in F6Publishing: 32] [Article Influence: 39.5] [Reference Citation Analysis]
48 Musacchio L, Caruso G, Pisano C, Cecere SC, Di Napoli M, Attademo L, Tambaro R, Russo D, Califano D, Palaia I, Muzii L, Benedetti Panici P, Pignata S. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives. Cancer Manag Res 2020;12:6123-35. [PMID: 32801862 DOI: 10.2147/CMAR.S221001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
49 Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martin-Lorente C, Poveda A, Gonzalez-Martin A. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res 2021;14:72. [PMID: 34039386 DOI: 10.1186/s13048-021-00816-x] [Reference Citation Analysis]
50 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
51 Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget 2017;8:44073-81. [PMID: 28454122 DOI: 10.18632/oncotarget.17237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
52 Xu Y, Ding L, Tian Y, Bi M, Han N, Wang L. Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Front Oncol 2020;10:573801. [PMID: 33692936 DOI: 10.3389/fonc.2020.573801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Herath NI, Berthault N, Thierry S, Jdey W, Lienafa MC, Bono F, Noguiez-Hellin P, Sun JS, Dutreix M. Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors. Front Oncol 2019;9:1097. [PMID: 31781480 DOI: 10.3389/fonc.2019.01097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
54 Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202-213. [PMID: 31158393 DOI: 10.1016/j.pharmthera.2019.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
55 Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B, Vizza E. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg 2020;9:1149-63. [PMID: 32953630 DOI: 10.21037/gs-20-413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Bian X, Lin W. Targeting DNA Replication Stress and DNA Double-Strand Break Repair for Optimizing SCLC Treatment. Cancers (Basel) 2019;11:E1289. [PMID: 31480716 DOI: 10.3390/cancers11091289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Ewing A, Meynert A, Churchman M, Grimes GR, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson M, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, McMahon L, Matakidou A, Dougherty B, March R, Barrett JC, McNeish IA, Biankin AV, Roxburgh P, Gourley C, Semple CA; Scottish Genomes Partnership. Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. Clin Cancer Res 2021;27:3201-14. [PMID: 33741650 DOI: 10.1158/1078-0432.CCR-20-4068] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wang L, Liang C, Li F, Guan D, Wu X, Fu X, Lu A, Zhang G. PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. Int J Mol Sci 2017;18:E2111. [PMID: 28991194 DOI: 10.3390/ijms18102111] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
59 Fukagawa S, Miyata K, Yotsumoto F, Kiyoshima C, Nam SO, Anan H, Katsuda T, Miyahara D, Murata M, Yagi H, Shirota K, Yasunaga S, Kato K, Miyamoto S. MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Sci 2017;108:886-96. [PMID: 28231414 DOI: 10.1111/cas.13210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
60 Tian S, Mi W, Zhang M, Xing L, Zhang C. Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures. J Cell Mol Med 2020;24:2582-92. [PMID: 31957240 DOI: 10.1111/jcmm.14968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Marchetti C, Rosati A, Scambia G, Fagotti A. Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something? Ann Transl Med 2019;7:S372. [PMID: 32016090 DOI: 10.21037/atm.2019.12.94] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
62 Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, Takahashi N, Abe M, Tanaka A, Nagasawa T, Shoji T, Xiong H, Nuthalapati S, Leahy T, Hashiba H, Kiriyama T, Komarnitsky P, Hirashima Y, Ushijima K. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci 2017;108:2213-20. [PMID: 28837250 DOI: 10.1111/cas.13381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
63 Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017;9:519-31. [PMID: 28794804 DOI: 10.1177/1758834017714993] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
64 Akce M, El-Khoueiry A, Piha-Paul SA, Bacque E, Pan P, Zhang ZY, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O'Bryant CL. Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemother Pharmacol 2021. [PMID: 34324028 DOI: 10.1007/s00280-021-04329-8] [Reference Citation Analysis]
65 van Baal JOAM, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, Kenter GG, Lok CAR. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J Histochem Cytochem 2018;66:67-83. [PMID: 29164988 DOI: 10.1369/0022155417742897] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
66 Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol 2019;37:2968-73. [PMID: 31173551 DOI: 10.1200/JCO.18.02238] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
67 Yang WH, Huang Z, Wu J, Ding CC, Murphy SK, Chi JT. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. Mol Cancer Res 2020;18:79-90. [PMID: 31641008 DOI: 10.1158/1541-7786.MCR-19-0691] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 23.0] [Reference Citation Analysis]
68 Montemorano L, Lightfoot MD, Bixel K. Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date. Onco Targets Ther 2019;12:11497-506. [PMID: 31920338 DOI: 10.2147/OTT.S195552] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
69 Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018;2018. [PMID: 30234181 DOI: 10.1200/PO.17.00286] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 18.7] [Reference Citation Analysis]
70 Wolford JE, Tewari KS. Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol 2017;28:e74. [PMID: 28758380 DOI: 10.3802/jgo.2017.28.e74] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
71 Mieulet V, Garnier C, Kieffer Y, Guilbert T, Nemati F, Marangoni E, Renault G, Chamming's F, Vincent-Salomon A, Mechta-Grigoriou F. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Sci Rep 2021;11:4219. [PMID: 33603134 DOI: 10.1038/s41598-021-83685-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Peixoto A, Pinto P, Guerra J, Pinheiro M, Santos C, Pinto C, Santos R, Escudeiro C, Bartosch C, Canário R, Barbosa A, Gouveia A, Petiz A, Abreu MH, Sousa S, Pereira D, Silva J, Teixeira MR. Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. Front Oncol 2020;10:1318. [PMID: 32850417 DOI: 10.3389/fonc.2020.01318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119:1075-85. [PMID: 30353045 DOI: 10.1038/s41416-018-0271-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 23.3] [Reference Citation Analysis]
74 Tao JJ, Schram AM, Hyman DM. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annu Rev Med 2018;69:319-31. [PMID: 29120700 DOI: 10.1146/annurev-med-062016-050343] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
75 Kalachand RD, O'Riain C, Toomey S, Carr A, Timms KM, O'Toole S, Madden S, Bates M, O'Leary JJ, Gleeson N, O'Donnell D, Grogan L, Breathnach O, Farrelly A, Stordal B, Hennessy BT. Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstet Gynecol Sci 2020;63:643-54. [PMID: 32872764 DOI: 10.5468/ogs.20033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M. Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. J Neurooncol 2017;133:469-76. [PMID: 28497333 DOI: 10.1007/s11060-017-2459-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
77 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel). 2019;11. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
78 Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer 2019:ijgc-2019-000499. [PMID: 31118216 DOI: 10.1136/ijgc-2019-000499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Nunes M, Henriques Abreu M, Bartosch C, Ricardo S. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. Int J Mol Sci 2020;21:E7768. [PMID: 33092251 DOI: 10.3390/ijms21207768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Nishimura M, Sakai H, Onoe T, Boku S, Yokoyama T, Kadokura G, Morita S, Katsumata N, Matsumoto K. 4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study. Int J Clin Oncol 2021;26:1553-60. [PMID: 34037884 DOI: 10.1007/s10147-021-01935-7] [Reference Citation Analysis]
81 Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer 2019;125:1963-72. [PMID: 30835824 DOI: 10.1002/cncr.32004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
82 Morosi L, Matteo C, Ceruti T, Giordano S, Ponzo M, Frapolli R, Zucchetti M, Davoli E, D'Incalci M, Ubezio P. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. Int J Biol Sci 2020;16:1363-75. [PMID: 32210725 DOI: 10.7150/ijbs.41395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
83 Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget 2017;8:23891-904. [PMID: 28055979 DOI: 10.18632/oncotarget.14409] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
84 Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 2018;37:341-51. [PMID: 28945226 DOI: 10.1038/onc.2017.326] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
85 Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol 2017;144:486-90. [PMID: 28109627 DOI: 10.1016/j.ygyno.2017.01.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
86 Domchek SM, Robson ME. Update on Genetic Testing in Gynecologic Cancer. J Clin Oncol 2019;37:2501-9. [PMID: 31403865 DOI: 10.1200/JCO.19.00363] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
87 Köbel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, Le ND, Cook LS. Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. Int J Gynecol Pathol 2019;38:353-62. [PMID: 29901523 DOI: 10.1097/PGP.0000000000000530] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
88 Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. J Pathol Clin Res 2020;6:252-62. [PMID: 32391646 DOI: 10.1002/cjp2.168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
89 de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT. Using whole-genome sequencing data to derive the homologous recombination deficiency scores. NPJ Breast Cancer 2020;6:33. [PMID: 32818150 DOI: 10.1038/s41523-020-0172-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
90 Geenen JJJ, Dackus GMHE, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema ADR, Beijnen JH, Schellens JHM, Linn SC. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. Int J Cancer 2021;148:3041-50. [PMID: 33539540 DOI: 10.1002/ijc.33498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Gomez MK, Illuzzi G, Colomer C, Churchman M, Hollis RL, O'Connor MJ, Gourley C, Leo E, Melton DW. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers (Basel) 2020;12:E1503. [PMID: 32526907 DOI: 10.3390/cancers12061503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
92 Hong SH. How to start niraparib in real-world Asian ovarian cancer patients? J Gynecol Oncol 2021;32:e36. [PMID: 33559417 DOI: 10.3802/jgo.2021.32.e36] [Reference Citation Analysis]
93 Wang C, Mbalaviele G. Role of APD-Ribosylation in Bone Health and Disease. Cells 2019;8:E1201. [PMID: 31590342 DOI: 10.3390/cells8101201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
95 McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 2018;7:212540. [PMID: 30116283 DOI: 10.7573/dic.212540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
96 Wu CE, Ng CT, Tan KT. Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations. J Pers Med 2021;11:357. [PMID: 33946955 DOI: 10.3390/jpm11050357] [Reference Citation Analysis]
97 Sipos A, Ujlaki G, Mikó E, Maka E, Szabó J, Uray K, Krasznai Z, Bai P. The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med 2021;27:33. [PMID: 33794773 DOI: 10.1186/s10020-021-00295-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
98 Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer 2020;20:185. [PMID: 32131779 DOI: 10.1186/s12885-020-6688-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
99 Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 2017;23:4066-76. [PMID: 28356425 DOI: 10.1158/1078-0432.CCR-16-2714] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 13.8] [Reference Citation Analysis]
100 Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT. Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. Onco Targets Ther 2021;14:3895-901. [PMID: 34234458 DOI: 10.2147/OTT.S317514] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018;29:1895-902. [PMID: 30137196 DOI: 10.1093/annonc/mdy263] [Cited by in Crossref: 128] [Cited by in F6Publishing: 96] [Article Influence: 64.0] [Reference Citation Analysis]
102 Lu TP, Kuo KT, Chen CH, Chang MC, Lin HP, Hu YH, Chiang YC, Cheng WF, Chen CA. Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. Cancers (Basel) 2019;11:E270. [PMID: 30823599 DOI: 10.3390/cancers11020270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
103 Neviere Z, De La Motte Rouge T, Floquet A, Johnson A, Berthet P, Joly F. How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. Ther Adv Med Oncol 2020;12:1758835919897530. [PMID: 32165926 DOI: 10.1177/1758835919897530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
104 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
105 Dholakia J, Scalise C, Arend RC. Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. Cancers (Basel) 2021;13:1694. [PMID: 33918476 DOI: 10.3390/cancers13071694] [Reference Citation Analysis]
106 Ladan MM, van Gent DC, Jager A. Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. Cancers (Basel) 2021;13:1004. [PMID: 33670893 DOI: 10.3390/cancers13051004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Ali R, Alblihy A, Toss MS, Algethami M, Al Sunni R, Green AR, Rakha EA, Madhusudan S. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Ther Adv Med Oncol 2020;12:1758835920974201. [PMID: 33425022 DOI: 10.1177/1758835920974201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
108 Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, Slamon D, Velculescu VE, Scharpf RB. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Rep 2018;25:2617-33. [PMID: 30485824 DOI: 10.1016/j.celrep.2018.10.096] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
109 Shi T, Jiang R, Yu J, Yang H, Tu D, Dai Z, Shen Y, Zhang Y, Cheng X, Jia H, Tu R, Wang H, Tang J, Luan Y, Cai S, Zang R; SGOG-OV/AICE Investigators. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. Br J Cancer 2018;119:12-8. [PMID: 29899395 DOI: 10.1038/s41416-018-0036-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
110 Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci 2019;20:E952. [PMID: 30813239 DOI: 10.3390/ijms20040952] [Cited by in Crossref: 104] [Cited by in F6Publishing: 68] [Article Influence: 52.0] [Reference Citation Analysis]
111 Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther 2020;213:107588. [PMID: 32450190 DOI: 10.1016/j.pharmthera.2020.107588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
112 Liu Y, Chanana P, Davila JI, Hou X, Zanfagnin V, McGehee CD, Goode EL, Polley EC, Haluska P, Weroha SJ, Wang C. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Sci Rep 2019;9:6314. [PMID: 31004097 DOI: 10.1038/s41598-019-42680-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
113 Macedo GS, Alemar B, Ashton-Prolla P. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genet Mol Biol 2019;42:215-31. [PMID: 31067289 DOI: 10.1590/1678-4685-GMB-2018-0104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
114 Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019;75:697-706. [PMID: 30617511 DOI: 10.1007/s00228-018-02621-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Hoppe MM, Jaynes P, Wardyn JD, Upadhyayula SS, Tan TZ, Lie S, Lim DGZ, Pang BNK, Lim S, P S Yeong J, Karnezis A, Chiu DS, Leung S, Huntsman DG, Sedukhina AS, Sato K, Topp MD, Scott CL, Choi H, Patel NR, Brown R, Kaye SB, Pitt JJ, Tan DSP, Jeyasekharan AD. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Mol Med 2021;13:e13366. [PMID: 33709473 DOI: 10.15252/emmm.202013366] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
116 Kassab MA, Yu X. The role of dePARylation in DNA damage repair and cancer suppression. DNA Repair (Amst) 2019;76:20-9. [PMID: 30807923 DOI: 10.1016/j.dnarep.2019.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
117 Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 2020;19:107. [PMID: 32563252 DOI: 10.1186/s12943-020-01227-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 30.0] [Reference Citation Analysis]
118 Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, Gouy S, Morice P, Bentivegna E, Maulard A, Adam J, Achimas-Cadariu P, Leary A. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. Cancers (Basel) 2020;12:E707. [PMID: 32192091 DOI: 10.3390/cancers12030707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
119 Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. Sci Rep 2020;10:12506. [PMID: 32719318 DOI: 10.1038/s41598-020-68176-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
120 Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep 2020;10:2585. [PMID: 32066817 DOI: 10.1038/s41598-020-59074-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
121 Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. J Natl Cancer Inst 2020;112:161-9. [PMID: 31076742 DOI: 10.1093/jnci/djz080] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
122 Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371-90. [PMID: 31191001 DOI: 10.2147/CMAR.S200524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 23.5] [Reference Citation Analysis]
123 Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol 2020;146:721-37. [PMID: 31786739 DOI: 10.1007/s00432-019-03097-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
124 Cortesi L, Piombino C, Toss A. Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors? J Pers Med 2021;11:245. [PMID: 33800556 DOI: 10.3390/jpm11040245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. J Clin Oncol 2021;39:1631-40. [PMID: 33560870 DOI: 10.1200/JCO.20.02785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
126 Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer 2020;20:204. [PMID: 32164585 DOI: 10.1186/s12885-020-6693-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecol Oncol 2019;154:420-5. [PMID: 31229298 DOI: 10.1016/j.ygyno.2019.05.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
128 Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer 2020;20:507. [PMID: 32493233 DOI: 10.1186/s12885-020-06948-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
129 Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 2018;24:777-83. [PMID: 29191972 DOI: 10.1158/1078-0432.CCR-17-1327] [Cited by in Crossref: 85] [Cited by in F6Publishing: 35] [Article Influence: 21.3] [Reference Citation Analysis]
130 Yang Y, Du N, Xie L, Jiang J, Mo J, Hong J, Mao D, Ng DM, Shi H. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World J Surg Oncol 2020;18:151. [PMID: 32622363 DOI: 10.1186/s12957-020-01931-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Flessner MF. Pharmacokinetic problems in peritoneal drug administration: an update after 20 years. Pleura Peritoneum 2016;1:183-91. [PMID: 30911622 DOI: 10.1515/pp-2016-0022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
132 Zhang J, Zheng H, Gao Y, Lou G, Yin R, Ji D, Li W, Wang W, Xia B, Wang D, Hou J, Yan J, Hei Y, Zhang ZY, Milton A, Wu X. Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer. Oncologist 2020;25:19-e10. [PMID: 31439812 DOI: 10.1634/theoncologist.2019-0565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 2021;53:42-51. [PMID: 33487630 DOI: 10.1038/s12276-021-00557-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
134 Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S. Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. Br J Cancer 2020;122:483-90. [PMID: 31813938 DOI: 10.1038/s41416-019-0674-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
135 Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G, Katsaros D. Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics (Basel) 2020;10:E146. [PMID: 32156035 DOI: 10.3390/diagnostics10030146] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
136 Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. Br J Cancer 2018;119:1060-6. [PMID: 30318511 DOI: 10.1038/s41416-018-0268-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
137 Hou WH, Chen SH, Yu X. Poly-ADP ribosylation in DNA damage response and cancer therapy. Mutat Res Rev Mutat Res 2019;780:82-91. [PMID: 31395352 DOI: 10.1016/j.mrrev.2017.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
138 Wallace K, Goble S, Isaacson J, Maloney L, Cameron T, Bedel J. Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Pharmacoeconomics 2019;37:1065-7. [PMID: 31172449 DOI: 10.1007/s40273-019-00815-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
139 Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, Habrand JL, Saintigny Y, Joly F. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 2017;8:69105-24. [PMID: 28978184 DOI: 10.18632/oncotarget.19079] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
140 Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 2019;8:29. [PMID: 31737426 DOI: 10.1186/s40164-019-0154-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
141 Christenson ES, Antonarakis ES. PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 2018;23:123-33. [PMID: 29595348 DOI: 10.1080/14728214.2018.1459563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
142 Owen DH, Williams TM, Bertino EM, Mo X, Webb A, Schweitzer C, Liu T, Roychowdhury S, Timmers CD, Otterson GA. Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer 2019;134:167-73. [PMID: 31319977 DOI: 10.1016/j.lungcan.2019.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. Cancer Cell 2019;35:519-533.e8. [PMID: 30889383 DOI: 10.1016/j.ccell.2019.02.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
144 Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Curr Oncol Rep 2019;21:42. [PMID: 30919167 DOI: 10.1007/s11912-019-0790-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
145 Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Rep 2018;23:100-11. [PMID: 29617652 DOI: 10.1016/j.celrep.2018.03.038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
146 Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. Br J Cancer 2018;119:683-92. [PMID: 30111871 DOI: 10.1038/s41416-018-0217-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
147 Cummings S, Roman SS, Saam J, Bernhisel R, Brown K, Lancaster JM, Usha L. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. J Ovarian Res 2021;14:61. [PMID: 33926482 DOI: 10.1186/s13048-021-00809-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol 2017;147:695-704. [PMID: 29037806 DOI: 10.1016/j.ygyno.2017.10.003] [Cited by in Crossref: 115] [Cited by in F6Publishing: 95] [Article Influence: 28.8] [Reference Citation Analysis]
149 Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist. 2019;24:319-326. [PMID: 30018131 DOI: 10.1634/theoncologist.2018-0117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
150 George A, Banerjee S, Kaye S. Olaparib and somatic BRCA mutations. Oncotarget 2017;8:43598-9. [PMID: 28611314 DOI: 10.18632/oncotarget.18419] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
151 Pei Y, Li K, Lou X, Wu Y, Dong X, Wang W, Li N, Zhang D, Cui W. miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer. Oncol Rep 2020;44:438-48. [PMID: 32468036 DOI: 10.3892/or.2020.7623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
152 Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM 3rd, Hickson I, Tatum NJ, Rakha EA, Madhusudan S. FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers (Basel) 2021;13:1866. [PMID: 33919707 DOI: 10.3390/cancers13081866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
153 Hu X, Huang W, Fan M. Emerging therapies for breast cancer. J Hematol Oncol 2017;10:98. [PMID: 28454587 DOI: 10.1186/s13045-017-0466-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
154 Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers? Oncologist 2019;24:1469-78. [PMID: 31320502 DOI: 10.1634/theoncologist.2019-0175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
155 Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst 2017;109. [PMID: 28521333 DOI: 10.1093/jnci/djx059] [Cited by in Crossref: 83] [Cited by in F6Publishing: 60] [Article Influence: 20.8] [Reference Citation Analysis]
156 Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep 2018;25:2972-2980.e5. [PMID: 30540933 DOI: 10.1016/j.celrep.2018.11.054] [Cited by in Crossref: 161] [Cited by in F6Publishing: 135] [Article Influence: 80.5] [Reference Citation Analysis]
157 Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol 2018;19:1. [PMID: 30535808 DOI: 10.1007/s11864-018-0572-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
158 Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 2019;10:3533-46. [PMID: 31191824 DOI: 10.18632/oncotarget.26947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
159 Majić A, Miše BP, Matković V, Belac Lovasić I, Katić K, Canjko I, Frobe A, Bajić Ž, Vrdoljak E. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. J Oncol 2020;2020:6423936. [PMID: 32655639 DOI: 10.1155/2020/6423936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Sekine M, Nishino K, Enomoto T. BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art. Cancers (Basel) 2021;13:2562. [PMID: 34071148 DOI: 10.3390/cancers13112562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Kong TW, Ryu HS, Kim SC, Enomoto T, Li J, Kim KH, Shim SH, Wang PH, Therasakvichya S, Kobayashi Y, Lee M, Shi T, Lee SW, Mikami M, Nagase S, Lim MC, Wang J, Wilailak S, Kim SW, Hong SH, Tan DS, Mandai M, Chang SJ, Huang RYJ, Ushijima K, Lee JY, Chen X, Ochiai K, Lee TS, Yang B, Kalam F, Lv Q, Ahmad MF, Yaznil MR, Modi KB, Manopunya M, Jeong DH, Lertkhachonsuk AA, Chung HH, Watari H, Jeon S. Asian Society of Gynecologic Oncology International Workshop 2018. J Gynecol Oncol 2019;30:e39. [PMID: 30740961 DOI: 10.3802/jgo.2019.30.e39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
162 Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2018;20:274-85. [PMID: 28815456 DOI: 10.1007/s12094-017-1719-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. Mol Cancer Ther 2018;17:1167-76. [PMID: 29626126 DOI: 10.1158/1535-7163.MCT-17-0834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
164 Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299-309. [PMID: 31723286 DOI: 10.1038/s41586-019-1730-1] [Cited by in Crossref: 322] [Cited by in F6Publishing: 249] [Article Influence: 161.0] [Reference Citation Analysis]
165 Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. Oncol Lett 2020;19:2629-38. [PMID: 32218813 DOI: 10.3892/ol.2020.11364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 716] [Article Influence: 220.5] [Reference Citation Analysis]
167 Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel). 2018;5:pii: E16. [PMID: 29389895 DOI: 10.3390/medicines5010016] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 20.3] [Reference Citation Analysis]
168 Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. J Clin Oncol 2019;37:3183-91. [PMID: 31518175 DOI: 10.1200/JCO.19.00917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
169 Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, Hennessy D, Makris C, Moehler M. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Target Oncol 2019;14:505-25. [PMID: 31535338 DOI: 10.1007/s11523-019-00665-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
170 Rizzo A, Napoli A, Roggiani F, Tomassetti A, Bagnoli M, Mezzanzanica D. One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer. Int J Mol Sci 2018;19:E2092. [PMID: 30029471 DOI: 10.3390/ijms19072092] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
171 Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, Swisher EM. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Oncologist 2020;25:e109-19. [PMID: 31575788 DOI: 10.1634/theoncologist.2019-0229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
172 Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018;118:938-946. [PMID: 29527010 DOI: 10.1038/s41416-018-0003-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
173 Bax HJ, Chauhan J, Stavraka C, Khiabany A, Nakamura M, Pellizzari G, Ilieva KM, Lombardi S, Gould HJ, Corrigan CJ, Till SJ, Katugampola S, Jones PS, Barton C, Winship A, Ghosh S, Montes A, Josephs DH, Spicer JF, Karagiannis SN. Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. Cells 2020;9:E1631. [PMID: 32645919 DOI: 10.3390/cells9071631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
174 Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, Rebmann V. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Front Oncol 2019;9:1015. [PMID: 31681568 DOI: 10.3389/fonc.2019.01015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
175 Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F, Magagna I, Gentric G, Costa A, Bonneau C, Mieulet V, Vincent-Salomon A, Mechta-Grigoriou F. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun 2018;9:1056. [PMID: 29535360 DOI: 10.1038/s41467-018-03348-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 28.7] [Reference Citation Analysis]
176 Gong W, Ni M, Chen Z, Zheng Z. Expression and clinical significance of methyl-CpG binding domain protein 2 in high-grade serous ovarian cancer. Oncol Lett 2020;20:2749-56. [PMID: 32782591 DOI: 10.3892/ol.2020.11836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
177 Herzog TJ, Monk BJ. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? Gynecol Oncol Res Pract 2017;4:13. [PMID: 28904804 DOI: 10.1186/s40661-017-0050-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
178 Amanam I, Chung V. Targeted Therapies for Pancreatic Cancer. Cancers (Basel) 2018;10:E36. [PMID: 29382159 DOI: 10.3390/cancers10020036] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 15.7] [Reference Citation Analysis]
179 Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget 2017;8:43653-61. [PMID: 28525389 DOI: 10.18632/oncotarget.17613] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 17.3] [Reference Citation Analysis]
180 Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in Cancer: An Update on Clinical Development. Target Oncol 2019;14:657-79. [PMID: 31625002 DOI: 10.1007/s11523-019-00680-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 37.0] [Reference Citation Analysis]
181 Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep 2019;9:1853. [PMID: 30755715 DOI: 10.1038/s41598-019-38534-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 39.0] [Reference Citation Analysis]
182 Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F. Niraparib in ovarian cancer: results to date and clinical potential. Ther Adv Med Oncol 2017;9:579-88. [PMID: 29081841 DOI: 10.1177/1758834017718775] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
183 Gray S, Khor XY, Yiannakis D. Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Rep 2019;12:e230738. [PMID: 31466953 DOI: 10.1136/bcr-2019-230738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
184 Moffitt L, Karimnia N, Stephens A, Bilandzic M. Therapeutic Targeting of Collective Invasion in Ovarian Cancer. Int J Mol Sci 2019;20:E1466. [PMID: 30909510 DOI: 10.3390/ijms20061466] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
185 Muñoz-Galván S, Carnero A. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells 2020;9:E1402. [PMID: 32512891 DOI: 10.3390/cells9061402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
186 Markman M. Pharmaceutical Management of Ovarian Cancer: Current Status. Drugs 2019;79:1231-9. [PMID: 31267481 DOI: 10.1007/s40265-019-01158-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
187 Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol Oncol. 2019;153:127-134. [PMID: 30686551 DOI: 10.1016/j.ygyno.2019.01.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
188 Colombo I, Lheureux S, Oza AM. Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Des Devel Ther. 2018;12:605-617. [PMID: 29606854 DOI: 10.2147/dddt.s130809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
189 Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. J Gynecol Oncol 2021;32:e16. [PMID: 33327047 DOI: 10.3802/jgo.2021.32.e16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 2017;14:284-96. [PMID: 27958297 DOI: 10.1038/nrclinonc.2016.191] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 18.0] [Reference Citation Analysis]
191 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
192 Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Sci Rep 2019;9:17808. [PMID: 31780705 DOI: 10.1038/s41598-019-54116-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
193 Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol 2021;161:653-9. [PMID: 33736856 DOI: 10.1016/j.ygyno.2021.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Pérez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells. Cancer Res 2021;81:2774-87. [PMID: 33514515 DOI: 10.1158/0008-5472.CAN-20-2912] [Reference Citation Analysis]
195 Guy H, Walder L, Fisher M. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. Pharmacoeconomics 2019;37:391-405. [PMID: 30478649 DOI: 10.1007/s40273-018-0745-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 17.0] [Reference Citation Analysis]
196 Min A, Im SA. PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. Cancers (Basel) 2020;12:E394. [PMID: 32046300 DOI: 10.3390/cancers12020394] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 33.0] [Reference Citation Analysis]
197 Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 2019;20:570-80. [PMID: 30880072 DOI: 10.1016/S1470-2045(18)30905-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 28] [Article Influence: 36.5] [Reference Citation Analysis]
198 Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019;116:9008-9013. [PMID: 30975761 DOI: 10.1073/pnas.1821510116] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 24.5] [Reference Citation Analysis]
199 Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. [PMID: 30672100 DOI: 10.1111/jcmm.14133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
200 Heo YA, Duggan ST. Niraparib: A Review in Ovarian Cancer. Target Oncol. 2018;13:533-539. [PMID: 30073633 DOI: 10.1007/s11523-018-0582-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
201 Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Ann Surg Oncol 2017;24:3116-23. [PMID: 28699130 DOI: 10.1245/s10434-017-5995-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
202 Zhen Y, Yu Y. Proteomic Analysis of the Downstream Signaling Network of PARP1. Biochemistry 2018;57:429-40. [PMID: 29327913 DOI: 10.1021/acs.biochem.7b01022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
203 Rizvi SMD, Alshammari AAA, Almawkaa WA, Ahmed ABF, Katamesh A, Alafnan A, Almutairi TJ, Alshammari RF. An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication. 3 Biotech 2019;9:70. [PMID: 30800581 DOI: 10.1007/s13205-019-1594-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
204 van der Lelij P, Lieb S, Jude J, Wutz G, Santos CP, Falkenberg K, Schlattl A, Ban J, Schwentner R, Hoffmann T, Kovar H, Real FX, Waldman T, Pearson MA, Kraut N, Peters JM, Zuber J, Petronczki M. Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife 2017;6:e26980. [PMID: 28691904 DOI: 10.7554/eLife.26980] [Cited by in Crossref: 52] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
205 Cunnea P, Fotopoulou C, Ploski J, Trillsch F, Mahner S, Kessler M. Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. Cancers (Basel) 2021;13:3349. [PMID: 34283069 DOI: 10.3390/cancers13133349] [Reference Citation Analysis]
206 Thomas A, Murai J, Pommier Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J Clin Invest 2018;128:1727-30. [PMID: 29664016 DOI: 10.1172/JCI120388] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
207 Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol 2020;31:1518-25. [PMID: 32798689 DOI: 10.1016/j.annonc.2020.08.2064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
208 Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. J Gynecol Oncol 2021;32:e21. [PMID: 33470063 DOI: 10.3802/jgo.2021.32.e21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
209 Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med 2019;381:2403-15. [PMID: 31562800 DOI: 10.1056/NEJMoa1909707] [Cited by in Crossref: 234] [Cited by in F6Publishing: 95] [Article Influence: 117.0] [Reference Citation Analysis]
210 Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 2020;19:711-36. [PMID: 32884152 DOI: 10.1038/s41573-020-0076-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 37.0] [Reference Citation Analysis]
211 Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G, Lorusso D. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers (Basel) 2021;13:1298. [PMID: 33803954 DOI: 10.3390/cancers13061298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Hentze JL, Høgdall C, Kjær SK, Blaakær J, Høgdall E. Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. Contemp Clin Trials Commun 2017;8:167-74. [PMID: 29696206 DOI: 10.1016/j.conctc.2017.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
213 Cho A, Park JY, Lee SW, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT. Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. Arch Gynecol Obstet 2021;304:1055-63. [PMID: 33871703 DOI: 10.1007/s00404-021-06013-x] [Reference Citation Analysis]
214 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
215 Lapke N, Chen CH, Chang TC, Chao A, Lu YJ, Lai CH, Tan KT, Chen HC, Lu HY, Chen SJ. Genetic alterations and their therapeutic implications in epithelial ovarian cancer. BMC Cancer 2021;21:499. [PMID: 33947352 DOI: 10.1186/s12885-021-08233-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs 2017;77:113-30. [PMID: 28078645 DOI: 10.1007/s40265-016-0688-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
217 Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017;14:549-61. [PMID: 28534531 DOI: 10.1038/nrclinonc.2017.71] [Cited by in Crossref: 151] [Cited by in F6Publishing: 135] [Article Influence: 37.8] [Reference Citation Analysis]
218 Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 2017;114:E9942-51. [PMID: 29093164 DOI: 10.1073/pnas.1707658114] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 20.8] [Reference Citation Analysis]
219 Gabrail N, Smith C. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. Am J Case Rep 2020;21:e927008. [PMID: 33191394 DOI: 10.12659/AJCR.927008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol 2020;38:1164-74. [PMID: 32073956 DOI: 10.1200/JCO.19.02745] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 51.0] [Reference Citation Analysis]
221 Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. [PMID: 28761758 DOI: 10.1136/esmoopen-2017-000166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
222 Lorusso D, García-Donas J, Sehouli J, Joly F. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Target Oncol 2020;15:391-406. [PMID: 32495160 DOI: 10.1007/s11523-020-00715-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
223 Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine 2019;40:375-81. [PMID: 30635165 DOI: 10.1016/j.ebiom.2018.12.060] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 19.0] [Reference Citation Analysis]
224 Wang J, Zhu J. Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib. Ann Transl Med 2021;9:869. [PMID: 34164503 DOI: 10.21037/atm-21-2252] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Exman P, Barroso-Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther 2019;12:5177-87. [PMID: 31303769 DOI: 10.2147/OTT.S184971] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
226 Anžič N, Krasniqi F, Eberhardt AL, Tzankov A, Haslbauer JD. Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study. Case Rep Oncol 2021;14:706-15. [PMID: 34177520 DOI: 10.1159/000515416] [Reference Citation Analysis]
227 Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q. PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer. NPJ Precis Oncol 2021;5:49. [PMID: 34108603 DOI: 10.1038/s41698-021-00189-w] [Reference Citation Analysis]
228 Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 2019;201:94-102. [PMID: 31128155 DOI: 10.1016/j.pharmthera.2019.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 25.0] [Reference Citation Analysis]
229 Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol 2019;155:144-50. [PMID: 31434613 DOI: 10.1016/j.ygyno.2019.08.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
230 Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:710-22. [PMID: 32359490 DOI: 10.1016/S1470-2045(20)30061-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 14.0] [Reference Citation Analysis]
231 Myers SH, Ortega JA, Cavalli A. Synthetic Lethality through the Lens of Medicinal Chemistry. J Med Chem 2020;63:14151-83. [PMID: 33135887 DOI: 10.1021/acs.jmedchem.0c00766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
232 Yoshida R, Hagio T, Kaneyasu T, Gotoh O, Osako T, Tanaka N, Amino S, Yaguchi N, Nakashima E, Kitagawa D, Ueno T, Ohno S, Nakajima T, Nakamura S, Miki Y, Hirota T, Takahashi S, Matsuura M, Noda T, Mori S. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Cancer Sci 2021;112:1310-9. [PMID: 33421217 DOI: 10.1111/cas.14803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
233 Yim GW, Suh DH, Kim JW, Kim SC, Kim YT. The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. J Gynecol Oncol 2019;30:e91. [PMID: 31140217 DOI: 10.3802/jgo.2019.30.e91] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
234 Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res 2020;32:370-82. [PMID: 32694901 DOI: 10.21147/j.issn.1000-9604.2020.03.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
235 Bradbury M, Borràs E, Pérez-Benavente A, Gil-Moreno A, Santamaria A, Sabidó E. Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers (Basel) 2021;13:2067. [PMID: 33922979 DOI: 10.3390/cancers13092067] [Reference Citation Analysis]
236 Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW. Major clinical research advances in gynecologic cancer in 2018. J Gynecol Oncol 2019;30:e18. [PMID: 30806045 DOI: 10.3802/jgo.2019.30.e18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
237 Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X. Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. J Ovarian Res 2020;13:29. [PMID: 32183851 DOI: 10.1186/s13048-020-00629-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res 2017;23:3711-20. [PMID: 28167507 DOI: 10.1158/1078-0432.CCR-16-3215] [Cited by in Crossref: 354] [Cited by in F6Publishing: 204] [Article Influence: 88.5] [Reference Citation Analysis]
239 Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J Ovarian Res 2019;12:40. [PMID: 31064392 DOI: 10.1186/s13048-019-0511-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
240 Yonemori K, Shimizu T, Kondo S, Iwasa S, Koyama T, Kitano S, Sato J, Shimomura A, Shibaki R, Suri A, Kase Y, Sumino S, Tamura K, Yamamoto N. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Jpn J Clin Oncol 2021;51:693-9. [PMID: 33621324 DOI: 10.1093/jjco/hyab013] [Reference Citation Analysis]
241 Caracciolo D, Riillo C, Di Martino MT, Tagliaferri P, Tassone P. Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel. Cancers (Basel) 2021;13:1392. [PMID: 33808562 DOI: 10.3390/cancers13061392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecol Oncol 2019;154:144-9. [PMID: 31113680 DOI: 10.1016/j.ygyno.2019.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
243 Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer 2017;123:1912-24. [PMID: 28323334 DOI: 10.1002/cncr.30631] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
244 Fields EC, McGuire WP, Lin L, Temkin SM. Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. Front Oncol 2017;7:177. [PMID: 28871275 DOI: 10.3389/fonc.2017.00177] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
245 Chen C, Chen S, Luo M, Yan H, Pang L, Zhu C, Tan W, Zhao Q, Lai J, Li H. The role of the CDCA gene family in ovarian cancer. Ann Transl Med 2020;8:190. [PMID: 32309337 DOI: 10.21037/atm.2020.01.99] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
246 Curtin N, Bányai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol 2020;177:3635-45. [PMID: 32441764 DOI: 10.1111/bph.15137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
247 Xia M, Guo Z, Hu Z. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. Biomolecules 2021;11:722. [PMID: 34066020 DOI: 10.3390/biom11050722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrère S, Quenet F, Gutowski M, Mourregot A, D'Hondt V, Coupier I, Vendrell J, Vilquin P, Pujol P, Solassol J, Mollevi C. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020;12:E2184. [PMID: 32764409 DOI: 10.3390/cancers12082184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
249 Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8:73240-73257. [PMID: 29069866 DOI: 10.18632/oncotarget.17291] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
250 Tookman L, Krell J, Nkolobe B, Burley L, McNeish IA. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Ther Adv Med Oncol 2020;12:1758835920921980. [PMID: 32523631 DOI: 10.1177/1758835920921980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther 2020;5:137. [PMID: 32728057 DOI: 10.1038/s41392-020-0199-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
252 Pasquier J, Gosset M, Geyl C, Hoarau-Véchot J, Chevrot A, Pocard M, Mirshahi M, Lis R, Rafii A, Touboul C. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer. Mol Cancer 2018;17:47. [PMID: 29455640 DOI: 10.1186/s12943-018-0787-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
253 Gee ME, Faraahi Z, McCormick A, Edmondson RJ. DNA damage repair in ovarian cancer: unlocking the heterogeneity. J Ovarian Res 2018;11:50. [PMID: 29925418 DOI: 10.1186/s13048-018-0424-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
254 Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J Gynecol Oncol 2021;32:e31. [PMID: 33559413 DOI: 10.3802/jgo.2021.32.e31] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S. BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. JNCI Cancer Spectr 2020;4:pkz100. [PMID: 32175521 DOI: 10.1093/jncics/pkz100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J. Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. Cancers (Basel) 2020;12:E3468. [PMID: 33233347 DOI: 10.3390/cancers12113468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
257 Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol 2020;156:13-22. [PMID: 31708167 DOI: 10.1016/j.ygyno.2019.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
258 Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol 2020;159:79-87. [PMID: 32723679 DOI: 10.1016/j.ygyno.2020.07.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med 2019;21:213-23. [PMID: 29961768 DOI: 10.1038/s41436-018-0009-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 21.7] [Reference Citation Analysis]
260 Kathawala RJ, Kudelka A, Rigas B. The Chemoprevention of Ovarian Cancer: the Need and the Options. Curr Pharmacol Rep 2018;4:250-60. [PMID: 30363743 DOI: 10.1007/s40495-018-0133-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
261 Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med 2019;8:E435. [PMID: 30934991 DOI: 10.3390/jcm8040435] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
262 Gilson C, Chowdhury S, Parmar MKB, Sydes MR; STAMPEDE Investigators. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clin Oncol (R Coll Radiol) 2017;29:778-86. [PMID: 29079227 DOI: 10.1016/j.clon.2017.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
263 Garzon S, Laganà AS, Casarin J, Raffaelli R, Cromi A, Franchi M, Barra F, Alkatout I, Ferrero S, Ghezzi F. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg 2020;9:1118-29. [PMID: 32953627 DOI: 10.21037/gs-20-325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Govindarajan M, Wohlmuth C, Waas M, Bernardini MQ, Kislinger T. High-throughput approaches for precision medicine in high-grade serous ovarian cancer. J Hematol Oncol 2020;13:134. [PMID: 33036656 DOI: 10.1186/s13045-020-00971-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
265 BrintzenhofeSzoc K, Krok-Schoen JL, Canin B, Parker I, MacKenzie AR, Koll T, Vankina R, Hsu CD, Jang B, Pan K, Lund JL, Starbuck E, Shahrokni A. The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. J Geriatr Oncol 2020;11:369-79. [PMID: 31932259 DOI: 10.1016/j.jgo.2019.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
266 Sauriol A, Simeone K, Portelance L, Meunier L, Leclerc-Desaulniers K, de Ladurantaye M, Chergui M, Kendall-Dupont J, Rahimi K, Carmona E, Provencher DM, Mes-Masson AM. Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. Cancers (Basel) 2020;12:E2222. [PMID: 32784519 DOI: 10.3390/cancers12082222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
267 Ahmed N, Kadife E, Raza A, Short M, Jubinsky PT, Kannourakis G. Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells 2020;9:E719. [PMID: 32183385 DOI: 10.3390/cells9030719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
268 Markman M. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Womens Health (Lond) 2018;14:1745505717750694. [PMID: 29313444 DOI: 10.1177/1745505717750694] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
269 Suh DH, Kim M, Kim K, Kim HJ, Lee KH, Kim JW. Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. J Gynecol Oncol 2017;28:e45. [PMID: 28382802 DOI: 10.3802/jgo.2017.28.e45] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
270 Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, Khabele D. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecol Oncol 2020;157:405-10. [PMID: 32044108 DOI: 10.1016/j.ygyno.2020.01.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
271 Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Biosci Rep 2020;40:BSR20192226. [PMID: 32096544 DOI: 10.1042/BSR20192226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
272 Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract 2017;4:4. [PMID: 28250960 DOI: 10.1186/s40661-017-0039-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
273 Heinze K, Rengsberger M, Gajda M, Jansen L, Osmers L, Oliveira-Ferrer L, Schmalfeldt B, Dürst M, Häfner N, Runnebaum IB. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. Clin Epigenetics 2021;13:15. [PMID: 33482905 DOI: 10.1186/s13148-021-01006-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res 2019;12:9. [PMID: 30691488 DOI: 10.1186/s13048-019-0484-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
275 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 112] [Article Influence: 135.0] [Reference Citation Analysis]
276 Faraoni I, Graziani G. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 2018;10:E487. [PMID: 30518089 DOI: 10.3390/cancers10120487] [Cited by in Crossref: 79] [Cited by in F6Publishing: 58] [Article Influence: 26.3] [Reference Citation Analysis]
277 Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol 2021;39:966-77. [PMID: 33197226 DOI: 10.1200/JCO.20.00892] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
278 Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol 2019;11:1758835919849753. [PMID: 31205507 DOI: 10.1177/1758835919849753] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
279 Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L. Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer. Oncotarget 2017;8:83063-74. [PMID: 29137324 DOI: 10.18632/oncotarget.20945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
280 Zhang X, He T, Li Y, Chen L, Liu H, Wu Y, Guo H. Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol 2020;11:613773. [PMID: 33584699 DOI: 10.3389/fimmu.2020.613773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
281 Chung R, Tyebally S, Chen D, Kapil V, Walker JM, Addison D, Ismail-Khan R, Guha A, Ghosh AK. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology. J Clin Med 2020;9:E3346. [PMID: 33081013 DOI: 10.3390/jcm9103346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Póti Á, Gyergyák H, Németh E, Rusz O, Tóth S, Kovácsházi C, Chen D, Szikriszt B, Spisák S, Takeda S, Szakács G, Szallasi Z, Richardson AL, Szüts D. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biol 2019;20:240. [PMID: 31727117 DOI: 10.1186/s13059-019-1867-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 17.0] [Reference Citation Analysis]
283 Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 2019;154:294-301. [PMID: 31174889 DOI: 10.1016/j.ygyno.2019.04.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
284 Den RB, George D, Pieczonka C, McNamara M. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection. Am J Clin Oncol 2019;42:399-406. [PMID: 30844849 DOI: 10.1097/COC.0000000000000528] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
285 Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW. Major clinical research advances in gynecologic cancer in 2017. J Gynecol Oncol 2018;29:e31. [PMID: 29468855 DOI: 10.3802/jgo.2018.29.e31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
286 Harada Y, Kubo M, Kai M, Yamada M, Zaguirre K, Ohgami T, Yahata H, Ohishi Y, Yamamoto H, Oda Y, Nakamura M. Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases. Surg Case Rep 2020;6:317. [PMID: 33300090 DOI: 10.1186/s40792-020-01090-7] [Reference Citation Analysis]
287 Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G. PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective. Oncol Lett 2020;20:90. [PMID: 32831909 DOI: 10.3892/ol.2020.11951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
288 Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ Jr, Hromas R. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol 2017;80:861-7. [PMID: 28756516 DOI: 10.1007/s00280-017-3401-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
289 Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget 2019;10:2855-68. [PMID: 31080557 DOI: 10.18632/oncotarget.26869] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
290 Tao M, Cheng J, Wu X. Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review. Onco Targets Ther 2020;13:12979-86. [PMID: 33376347 DOI: 10.2147/OTT.S281302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Sisay M, Edessa D. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecol Oncol Res Pract 2017;4:18. [PMID: 29214031 DOI: 10.1186/s40661-017-0055-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
292 Zhang MX, Hong SS, Cai QQ, Zhang M, Chen J, Zhang XY, Xu CJ. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo. Drug Deliv 2018;25:797-806. [PMID: 29542355 DOI: 10.1080/10717544.2018.1451934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
293 Tutuncuoglu B, Krogan NJ. Mapping genetic interactions in cancer: a road to rational combination therapies. Genome Med 2019;11:62. [PMID: 31640753 DOI: 10.1186/s13073-019-0680-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
294 Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog 2019;58:1770-82. [PMID: 31219654 DOI: 10.1002/mc.23064] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
295 Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D. Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells 2019;8:E200. [PMID: 30813545 DOI: 10.3390/cells8030200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
296 Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int J Mol Sci 2018;19:E3249. [PMID: 30347758 DOI: 10.3390/ijms19103249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 McIntosh MT, Koganti S, Boatwright JL, Li X, Spadaro SV, Brantly AC, Ayers JB, Perez RD, Burton EM, Burgula S, MacCarthy T, Bhaduri-McIntosh S. STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes. PLoS Pathog 2020;16:e1008849. [PMID: 33002095 DOI: 10.1371/journal.ppat.1008849] [Reference Citation Analysis]
298 Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. J Ovarian Res 2021;14:68. [PMID: 33993885 DOI: 10.1186/s13048-021-00803-2] [Reference Citation Analysis]
299 Wu SG, Wang J, Sun JY, He ZY, Zhang WW, Zhou J. Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014. Front Oncol 2019;9:639. [PMID: 31448220 DOI: 10.3389/fonc.2019.00639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
300 Mengwasser KE, Adeyemi RO, Leng Y, Choi MY, Clairmont C, D'Andrea AD, Elledge SJ. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. Mol Cell 2019;73:885-899.e6. [PMID: 30686591 DOI: 10.1016/j.molcel.2018.12.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 32.0] [Reference Citation Analysis]
301 Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17:577-591. [PMID: 28468520 DOI: 10.1080/14737159.2017.1326820] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
302 Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL. Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers (Basel) 2019;11:E354. [PMID: 30871186 DOI: 10.3390/cancers11030354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
303 Dall'Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G, Califano D, Bagnoli M, Militello L, Mezzanzanica D, Chiappetta G, Armenia J, Belletti B, Schiappacassi M, Baldassarre G. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med 2017;9:1415-33. [PMID: 28778953 DOI: 10.15252/emmm.201607012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
304 Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 2020;59:102923. [PMID: 32799124 DOI: 10.1016/j.ebiom.2020.102923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
305 Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. J Natl Cancer Inst 2021;113:917-23. [PMID: 33372675 DOI: 10.1093/jnci/djaa193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
306 Sung PL, Wen KC, Chen YJ, Chao TC, Tsai YF, Tseng LM, Qiu JT, Chao KC, Wu HH, Chuang CM, Wang PH, Huang CF. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels. PLoS One 2017;12:e0185615. [PMID: 28961279 DOI: 10.1371/journal.pone.0185615] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
307 Xu Y, Guo X, Wang G, Zhou C. Vitamin C Inhibits Metastasis of Peritoneal Tumors By Preventing Spheroid Formation in ID8 Murine Epithelial Peritoneal Cancer Model. Front Pharmacol 2020;11:645. [PMID: 32477126 DOI: 10.3389/fphar.2020.00645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Klempner SJ, Bhangoo MS, Luu HY, Kim ST, Chao J, Kim KM, Lee J. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. J Gastrointest Oncol 2018;9:1198-206. [PMID: 30603142 DOI: 10.21037/jgo.2018.09.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Zhang G, Liu C, Bai H, Cao G, Cui R, Zhang Z. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. Oncol Lett 2019;17:2583-91. [PMID: 30854033 DOI: 10.3892/ol.2019.9902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
310 Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, Birkbak NJ, Eklund AC, Syed A, Szallasi Z. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 2018;4:16. [PMID: 29978035 DOI: 10.1038/s41523-018-0066-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
311 Desai D, Khandwala P, Parsi M, Potdar R. PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. Med Oncol 2021;38:61. [PMID: 33891252 DOI: 10.1007/s12032-021-01507-9] [Reference Citation Analysis]
312 Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ. Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Curr Treat Options Cardiovasc Med 2018;20:18. [PMID: 29497862 DOI: 10.1007/s11936-018-0609-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
313 Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2017;11:3009-17. [PMID: 29075104 DOI: 10.2147/DDDT.S147726] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
314 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
315 Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". Diagnostics (Basel) 2019;9:E55. [PMID: 31109041 DOI: 10.3390/diagnostics9020055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
316 Adashek JJ, Jain RK, Zhang J. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. Cells 2019;8:E860. [PMID: 31404966 DOI: 10.3390/cells8080860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
317 Faraoni I, Consalvo MI, Aloisio F, Fabiani E, Giansanti M, Di Cristino F, Falconi G, Tentori L, Di Veroli A, Curzi P, Maurillo L, Niscola P, Lo-Coco F, Graziani G, Voso MT. Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers (Basel) 2019;11:E1373. [PMID: 31527467 DOI: 10.3390/cancers11091373] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
318 Santana Dos Santos E, Lallemand F, Burke L, Stoppa-Lyonnet D, Brown M, Caputo SM, Rouleau E. Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. Cancers (Basel) 2018;10:E453. [PMID: 30453575 DOI: 10.3390/cancers10110453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
319 Pan K, Gong J, Huynh K, Cristea M. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Target Oncol 2019;14:269-83. [PMID: 31069647 DOI: 10.1007/s11523-019-00641-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
320 Chen W, Li Z, Zheng Z, Wu X. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. Cancer Med 2020;9:5899-907. [PMID: 32627959 DOI: 10.1002/cam4.3282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
321 Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci 2017;108:1834-42. [PMID: 28665051 DOI: 10.1111/cas.13307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
322 Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30:903-15. [PMID: 32276934 DOI: 10.1136/ijgc-2020-001288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
323 Shi T, Yin S, Zhu J, Zhang P, Liu J, Zhu Y, Wu S, Chen X, Wang X, Teng Y, Zhu T, Yu A, Zhang Y, Feng Y, Huang H, Bao W, Li Y, Jiang W, Zhang P, Li J, Ai Z, Zhang W, Jia H, Zhang Y, Jiang R, Zhang J, Gao W, Luan Y, Zang R. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. J Gynecol Oncol 2020;31:e61. [PMID: 32319233 DOI: 10.3802/jgo.2020.31.e61] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
324 Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC. Implementing a comprehensive translational oncology platform: from molecular testing to actionability. J Transl Med 2018;16:358. [PMID: 30551737 DOI: 10.1186/s12967-018-1733-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
325 Stemmer A, Shafran I, Stemmer SM, Tsoref D. Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. Cancers (Basel) 2020;12:E3026. [PMID: 33081005 DOI: 10.3390/cancers12103026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
326 Alonso-Alconada L, de la Fuente A, Santacana M, Ferreiros A, Lopez-Lopez R, Matias-Guiu X, Abal M. Biomimetic device and foreign body reaction cooperate for efficient tumour cell capture in murine advanced ovarian cancer. Dis Model Mech 2020;13:dmm043653. [PMID: 32764154 DOI: 10.1242/dmm.043653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, Zhao M, Yang Q, Wang Y, Yang X. Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Front Oncol 2020;10:954. [PMID: 32719741 DOI: 10.3389/fonc.2020.00954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
328 Borella F, Bertero L, Morrone A, Gambella A, Bovetti M, Cosma S, Carosso A, Katsaros D, Gemmiti S, Preti M, Valabrega G, Scotto G, Cassoni P, Benedetto C. Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. Cancers (Basel) 2020;12:E2156. [PMID: 32759682 DOI: 10.3390/cancers12082156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
329 Tan DS, Tan DS, Tan IBH, Yan B, Choo SP, Chng WJ, Hwang WYK. Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. Asia Pac J Clin Oncol 2020;16:222-31. [PMID: 32301274 DOI: 10.1111/ajco.13339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
330 Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer 2021;12:38-53. [PMID: 33391401 DOI: 10.7150/jca.49406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
331 Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L. Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy. Oncologist 2019;24:e1471-5. [PMID: 31346131 DOI: 10.1634/theoncologist.2019-0272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
332 Favier L, Truc G, Boidot R, Bengrine-Lefevre L. Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report. Mol Clin Oncol 2020;13:73-5. [PMID: 32454976 DOI: 10.3892/mco.2020.2035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
333 Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, Nguyen B, Erakky A, Cadoo K, Liu Y, Carlo MI, Latham A, Zhang H, Kundra R, Smith S, Galle J, Aghajanian C, Abu-Rustum N, Varghese A, O'Reilly EM, Morris M, Abida W, Walsh M, Drilon A, Jayakumaran G, Zehir A, Ladanyi M, Ceyhan-Birsoy O, Solit DB, Schultz N, Berger MF, Mandelker D, Diaz LA Jr, Offit K, Robson ME. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. J Clin Oncol 2021;39:2698-709. [PMID: 34133209 DOI: 10.1200/JCO.20.03661] [Reference Citation Analysis]
334 Li Z, Liu Y, Fang X, Shu Z. Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. Int J Nanomedicine 2021;16:1631-61. [PMID: 33688183 DOI: 10.2147/IJN.S290346] [Reference Citation Analysis]
335 Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, Leong SCY, Liu G, Johnson D, Chen B, Group A, Alsop J, Banerjee SN, Behrens S, Bodelon C, Brand AH, Brinton L, Carney ME, Chiew YE, Cushing-Haugen KL, Cybulski C, Ennis D, Fereday S, Fortner RT, García-Donas J, Gentry-Maharaj A, Glasspool R, Goranova T, Greene CS, Haluska P, Harris HR, Hendley J, Hernandez BY, Herpel E, Jimenez-Linan M, Karpinskyj C, Kaufmann SH, Keeney GL, Kennedy CJ, Köbel M, Koziak JM, Larson MC, Lester J, Lewsley LA, Lissowska J, Lubiński J, Luk H, Macintyre G, Mahner S, McNeish IA, Menkiszak J, Nevins N, Osorio A, Oszurek O, Palacios J, Hinsley S, Pearce CL, Pike MC, Piskorz AM, Ray-Coquard I, Rhenius V, Rodriguez-Antona C, Sharma R, Sherman ME, De Silva D, Singh N, Sinn P, Slamon D, Song H, Steed H, Stronach EA, Thompson PJ, Tołoczko A, Trabert B, Traficante N, Tseng CC, Widschwendter M, Wilkens LR, Winham SJ, Winterhoff B, Beeghly-Fadiel A, Benitez J, Berchuck A, Brenton JD, Brown R, Chang-Claude J, Chenevix-Trench G, deFazio A, Fasching PA, García MJ, Gayther SA, Goodman MT, Gronwald J, Henderson MJ, Karlan BY, Kelemen LE, Menon U, Orsulic S, Pharoah PDP, Wentzensen N, Wu AH, Schildkraut JM, Rossing MA, Konecny GE, Huntsman DG, Huang RY, Goode EL, Ramus SJ, Doherty JA, Bowtell DD, Anglesio MS. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clin Cancer Res 2020;26:5411-23. [PMID: 32554541 DOI: 10.1158/1078-0432.CCR-20-0103] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
336 Zivanovic O, Chi DS, Filippova O, Randall LM, Bristow RE, O'Cearbhaill RE. It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol 2018;151:555-61. [PMID: 30249527 DOI: 10.1016/j.ygyno.2018.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
337 Kim DS, Challa S, Jones A, Kraus WL. PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis. Genes Dev 2020;34:302-20. [PMID: 32029452 DOI: 10.1101/gad.334433.119] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 38.0] [Reference Citation Analysis]
338 Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. J Pancreat Cancer 2020;6:107-15. [PMID: 33376937 DOI: 10.1089/pancan.2020.0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Mills K, Fuh K. Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res 2017;6:84. [PMID: 28184293 DOI: 10.12688/f1000research.9977.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
340 Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL. ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. Mol Cancer Ther 2020;19:282-91. [PMID: 31594824 DOI: 10.1158/1535-7163.MCT-19-0569] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
341 Yum S, Li M, Chen ZJ. Old dogs, new trick: classic cancer therapies activate cGAS. Cell Res 2020;30:639-48. [PMID: 32541866 DOI: 10.1038/s41422-020-0346-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
342 Elyashiv O, Wong YNS, Ledermann JA. Frontline Maintenance Treatment for Ovarian Cancer. Curr Oncol Rep 2021;23:97. [PMID: 34125335 DOI: 10.1007/s11912-021-01088-w] [Reference Citation Analysis]
343 Wang Y, Xu J, Luo N, Qi C, Tao R. Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab. Invest New Drugs 2021;39:1432-5. [PMID: 33851364 DOI: 10.1007/s10637-021-01116-3] [Reference Citation Analysis]
344 Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov 2018;17:183-96. [PMID: 29217837 DOI: 10.1038/nrd.2017.226] [Cited by in Crossref: 147] [Cited by in F6Publishing: 100] [Article Influence: 36.8] [Reference Citation Analysis]
345 Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16:81-104. [PMID: 30356138 DOI: 10.1038/s41571-018-0114-z] [Cited by in Crossref: 285] [Cited by in F6Publishing: 229] [Article Influence: 142.5] [Reference Citation Analysis]
346 Akaev I, Rahimi S, Onifade O, Gardner FJE, Castells-Rufas D, Jones E, Acharige S, Yeoh CC. Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom. Diagnostics (Basel) 2021;11:547. [PMID: 33808557 DOI: 10.3390/diagnostics11030547] [Reference Citation Analysis]
347 Yamashita H, Nakayama K, Ishikawa M, Ishibashi T, Nakamura K, Sawada K, Yoshimura Y, Tatsumi N, Kurose S, Minamoto T, Iida K, Razia S, Ishikawa N, Kyo S. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. Int J Mol Sci 2019;20:E5129. [PMID: 31623180 DOI: 10.3390/ijms20205129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
348 Miller EM, Patterson NE, Gressel GM, Karabakhtsian RG, Bejerano-Sagie M, Ravi N, Maslov A, Quispe-Tintaya W, Wang T, Lin J, Smith HO, Goldberg GL, Kuo DYS, Montagna C. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups. BMC Med Genomics 2020;13:179. [PMID: 33256706 DOI: 10.1186/s12920-020-00824-8] [Reference Citation Analysis]
349 van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG. The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. Cancers (Basel) 2021;13:2994. [PMID: 34203855 DOI: 10.3390/cancers13122994] [Reference Citation Analysis]
350 Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol 2018;29:1948-54. [PMID: 29917049 DOI: 10.1093/annonc/mdy216] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
351 Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R, Zou Y. PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res 2021;40:211. [PMID: 34167572 DOI: 10.1186/s13046-021-02005-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019;69:305-43. [PMID: 31116423 DOI: 10.3322/caac.21560] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 23.5] [Reference Citation Analysis]
353 Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist 2019;24:1340-7. [PMID: 31040255 DOI: 10.1634/theoncologist.2019-0034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
354 Lim HC, Gordan JD. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Comput Biol 2021;17:e1008699. [PMID: 33561166 DOI: 10.1371/journal.pcbi.1008699] [Reference Citation Analysis]
355 Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017;29:26-34. [PMID: 27898521 DOI: 10.1097/gco.0000000000000340] [Cited by in Crossref: 96] [Cited by in F6Publishing: 60] [Article Influence: 24.0] [Reference Citation Analysis]
356 Lawrence B, Blenkiron C, Parker K, Tsai P, Fitzgerald S, Shields P, Robb T, Yeong ML, Kramer N, James S, Black M, Fan V, Poonawala N, Yap P, Coats E, Woodhouse B, Ramsaroop R, Yozu M, Robinson B, Henare K, Koea J, Johnston P, Carroll R, Connor S, Morrin H, Elston M, Jackson C, Reid P, Windsor J, MacCormick A, Babor R, Bartlett A, Damianovich D, Knowlton N, Grimmond S, Findlay M, Print C. Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. NPJ Genom Med 2018;3:18. [PMID: 30062048 DOI: 10.1038/s41525-018-0058-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
357 Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L. Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. Br J Cancer 2021;125:7-14. [PMID: 33767416 DOI: 10.1038/s41416-021-01295-z] [Reference Citation Analysis]
358 Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, Cai X. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13:118. [PMID: 32883316 DOI: 10.1186/s13045-020-00956-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
359 Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther 2018;12:3013-9. [PMID: 30271116 DOI: 10.2147/DDDT.S164553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
360 Garje R, Vaddepally RK, Zakharia Y. PARP Inhibitors in Prostate and Urothelial Cancers. Front Oncol 2020;10:114. [PMID: 32117762 DOI: 10.3389/fonc.2020.00114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
361 Wang YT, Yuan B, Chen HD, Xu L, Tian YN, Zhang A, He JX, Miao ZH. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Sci 2018;109:821-31. [PMID: 29274141 DOI: 10.1111/cas.13477] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
362 Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang L. PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials. Front Oncol 2020;10:1204. [PMID: 32850351 DOI: 10.3389/fonc.2020.01204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
363 Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer 2018;119:141-52. [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 23.0] [Reference Citation Analysis]
364 Lin PH, Chen M, Tsai LW, Lo C, Yen TC, Huang TY, Chen CK, Fan SC, Kuo SH, Huang CS. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Cancer Sci 2020;111:1375-84. [PMID: 31958182 DOI: 10.1111/cas.14313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
365 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev 2020;34:360-94. [PMID: 32029455 DOI: 10.1101/gad.334516.119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 83.0] [Reference Citation Analysis]
366 Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest 2018;128:2116-26. [PMID: 29509546 DOI: 10.1172/JCI97992] [Cited by in Crossref: 52] [Cited by in F6Publishing: 25] [Article Influence: 17.3] [Reference Citation Analysis]
367 Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW, Knudsen S, Hansen A, Jensen PB, Jensen T, Mirza MR, Ekmann-Gade AW, Nedergaard L, Høgdall E. Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS One 2017;12:e0174300. [PMID: 28334047 DOI: 10.1371/journal.pone.0174300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
368 Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I. Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. J Gynecol Oncol 2021;32:e82. [PMID: 34378365 DOI: 10.3802/jgo.2021.32.e82] [Reference Citation Analysis]
369 Funnell T, Zhang AW, Grewal D, McKinney S, Bashashati A, Wang YK, Shah SP. Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. PLoS Comput Biol 2019;15:e1006799. [PMID: 30794536 DOI: 10.1371/journal.pcbi.1006799] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
370 Teply BA, Antonarakis ES. Treatment strategies for DNA repair-deficient prostate cancer. Expert Rev Clin Pharmacol 2017;10:889-98. [PMID: 28573914 DOI: 10.1080/17512433.2017.1338138] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
371 Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021;27:1943-58. [PMID: 34007132 DOI: 10.3748/wjg.v27.i17.1943] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Ali R, Alblihy A, Miligy IM, Alabdullah ML, Alsaleem M, Toss MS, Algethami M, Abdel-Fatah T, Moseley P, Chan S, Mongan NP, Narayan S, Rakha EA, Madhusudan S. Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene 2021;40:2496-508. [PMID: 33674744 DOI: 10.1038/s41388-021-01710-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer 2021;3:zcab028. [PMID: 34316715 DOI: 10.1093/narcan/zcab028] [Reference Citation Analysis]
374 Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int J Mol Sci 2020;21:E3805. [PMID: 32471250 DOI: 10.3390/ijms21113805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
375 Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 2018;10:e9172. [PMID: 30377213 DOI: 10.15252/emmm.201809172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 32.0] [Reference Citation Analysis]
376 da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. BMC Cancer 2019;19:422. [PMID: 31060523 DOI: 10.1186/s12885-019-5622-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
377 Gonçalves A, Bertucci A, Bertucci F. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? Cancers (Basel) 2020;12:E1378. [PMID: 32471249 DOI: 10.3390/cancers12061378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
378 Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res 2019;79:311-9. [PMID: 30482774 DOI: 10.1158/0008-5472.CAN-18-1003] [Cited by in Crossref: 162] [Cited by in F6Publishing: 91] [Article Influence: 54.0] [Reference Citation Analysis]
379 Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecol Oncol 2020;157:214-21. [PMID: 31959492 DOI: 10.1016/j.ygyno.2020.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer. 2018;119:1401-1409. [PMID: 30353044 DOI: 10.1038/s41416-018-0274-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 22.3] [Reference Citation Analysis]
381 Wang Y, Luo W, Wang Y. PARP-1 and its associated nucleases in DNA damage response. DNA Repair (Amst) 2019;81:102651. [PMID: 31302005 DOI: 10.1016/j.dnarep.2019.102651] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
382 Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 2019;110:1064-75. [PMID: 30663191 DOI: 10.1111/cas.13947] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
383 Bahar E, Kim JY, Kim DC, Kim HS, Yoon H. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. Int J Mol Sci 2021;22:3916. [PMID: 33920140 DOI: 10.3390/ijms22083916] [Reference Citation Analysis]
384 Bakrin N, Tempfer C, Scambia G, De Simone M, Gabriel B, Grischke EM, Rau B. PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Pleura Peritoneum 2018;3:20180114. [PMID: 30911662 DOI: 10.1515/pp-2018-0114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
385 Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol 2018;10:1758835918778483. [PMID: 29977351 DOI: 10.1177/1758835918778483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
386 Chowdhury S, Mainwaring P, Zhang L, Mundle S, Pollozi E, Gray A, Wildgust M. Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. Front Oncol 2020;10:1349. [PMID: 32923387 DOI: 10.3389/fonc.2020.01349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
387 Hollis RL, Churchman M, Gourley C. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther 2017;10:2539-51. [PMID: 28546758 DOI: 10.2147/OTT.S102569] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
388 Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discov. 2018;8:49-58. [PMID: 29122777 DOI: 10.1158/2159-8290.cd-17-0787] [Cited by in Crossref: 131] [Cited by in F6Publishing: 86] [Article Influence: 32.8] [Reference Citation Analysis]
389 Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis 2018;35:521-33. [PMID: 29931499 DOI: 10.1007/s10585-018-9889-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
390 Martinez A, Delord JP, Ayyoub M, Devaud C. Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers (Basel) 2020;12:E1761. [PMID: 32630708 DOI: 10.3390/cancers12071761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
391 Caron MC, Sharma AK, O'Sullivan J, Myler LR, Ferreira MT, Rodrigue A, Coulombe Y, Ethier C, Gagné JP, Langelier MF, Pascal JM, Finkelstein IJ, Hendzel MJ, Poirier GG, Masson JY. Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat Commun 2019;10:2954. [PMID: 31273204 DOI: 10.1038/s41467-019-10741-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 20.0] [Reference Citation Analysis]
392 Soliman AA, Elzarkaa AA, Malik E. Epithelial Ovarian Cancer and Cancer Stem Cells. Adv Exp Med Biol 2021;1330:21-32. [PMID: 34339028 DOI: 10.1007/978-3-030-73359-9_2] [Reference Citation Analysis]
393 Kim DS, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL. Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21. Mol Cell 2019;75:1270-1285.e14. [PMID: 31351877 DOI: 10.1016/j.molcel.2019.06.020] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 31.0] [Reference Citation Analysis]
394 Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, Shen L, Xue Y, Jiang K, Luo F, Liu P, Cheng H. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine 2019;43:225-37. [PMID: 30898650 DOI: 10.1016/j.ebiom.2019.03.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
395 Mazzarella L. Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8-9 February 2018. Ecancermedicalscience 2018;12:817. [PMID: 29662530 DOI: 10.3332/ecancer.2018.817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
396 Zhu Y, Liu J, Park J, Rai P, Zhai RG. Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. Pharmacol Ther 2019;200:27-41. [PMID: 30974124 DOI: 10.1016/j.pharmthera.2019.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
397 Estati FL, Pirolli R, de Alencar VTL, Ribeiro ARG, Formiga MN, Torrezan GT, Carraro DM, Guimarães APG, Baiocchi G, da Costa AABA. Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery. Ann Surg Oncol 2021;28:3637-45. [PMID: 33221980 DOI: 10.1245/s10434-020-09366-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
398 Santandrea G, Piana S, Valli R, Zanelli M, Gasparini E, De Leo A, Mandato VD, Palicelli A. Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics (Basel) 2021;11:199. [PMID: 33572888 DOI: 10.3390/diagnostics11020199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
399 Chi J, Chung SY, Parakrama R, Fayyaz F, Jose J, Saif MW. The role of PARP inhibitors in BRCA mutated pancreatic cancer. Therap Adv Gastroenterol 2021;14:17562848211014818. [PMID: 34025781 DOI: 10.1177/17562848211014818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol 2018;14:3101-10. [PMID: 30105925 DOI: 10.2217/fon-2018-0215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
401 Hendriks IA, Larsen SC, Nielsen ML. An Advanced Strategy for Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics. Mol Cell Proteomics 2019;18:1010-26. [PMID: 30798302 DOI: 10.1074/mcp.TIR119.001315] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
402 Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ. Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus 2019;11:e5197. [PMID: 31565603 DOI: 10.7759/cureus.5197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
403 Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res 2019;12:103. [PMID: 31685032 DOI: 10.1186/s13048-019-0579-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
404 Wagener-Ryczek S, Merkelbach-Bruse S, Siemanowski J. Biomarkers for Homologous Recombination Deficiency in Cancer. J Pers Med 2021;11:612. [PMID: 34203281 DOI: 10.3390/jpm11070612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Shin DW, Bae J, Ha J, Jung KW. Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study. Front Oncol 2021;11:639839. [PMID: 33996553 DOI: 10.3389/fonc.2021.639839] [Reference Citation Analysis]
406 Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers (Basel) 2019;11:E774. [PMID: 31167492 DOI: 10.3390/cancers11060774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
407 Hatano Y, Hatano K, Tamada M, Morishige KI, Tomita H, Yanai H, Hara A. A Comprehensive Review of Ovarian Serous Carcinoma. Adv Anat Pathol 2019;26:329-39. [PMID: 31368906 DOI: 10.1097/PAP.0000000000000243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
408 Hou D, Liu Z, Xu X, Liu Q, Zhang X, Kong B, Wei JJ, Gong Y, Shao C. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer. Redox Biol 2018;17:99-111. [PMID: 29684820 DOI: 10.1016/j.redox.2018.03.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
409 Sharifi-Rad J, Ozleyen A, Boyunegmez Tumer T, Oluwaseun Adetunji C, El Omari N, Balahbib A, Taheri Y, Bouyahya A, Martorell M, Martins N, Cho WC. Natural Products and Synthetic Analogs as a Source of Antitumor Drugs. Biomolecules 2019;9:E679. [PMID: 31683894 DOI: 10.3390/biom9110679] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 16.0] [Reference Citation Analysis]
410 Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL; Australian Ovarian Cancer Study (AOCS). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 2018;9:3970. [PMID: 30266954 DOI: 10.1038/s41467-018-05564-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 27.7] [Reference Citation Analysis]
411 Valabrega G, Scotto G, Tuninetti V, Pani A, Scaglione F. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. Int J Mol Sci 2021;22:4203. [PMID: 33921561 DOI: 10.3390/ijms22084203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer 2021;20:27. [PMID: 33541368 DOI: 10.1186/s12943-021-01317-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
413 Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501-9. [PMID: 29881257 DOI: 10.2147/DDDT.S124447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
414 van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol 2018;81:39-46. [PMID: 29043410 DOI: 10.1007/s00280-017-3455-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
415 Francis J, Coakley N, Elit L, Mackay H; Gynecologic Cancer Disease Site Group. Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Curr Oncol 2017;24:e540-6. [PMID: 29270064 DOI: 10.3747/co.24.3824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
416 Das S, Camphausen K, Shankavaram U. Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response. Front Oncol 2019;9:1136. [PMID: 31709193 DOI: 10.3389/fonc.2019.01136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
417 Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 2017;7:984-98. [PMID: 28588062 DOI: 10.1158/2159-8290.CD-17-0419] [Cited by in Crossref: 154] [Cited by in F6Publishing: 77] [Article Influence: 38.5] [Reference Citation Analysis]
418 Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Synthetic Lethality in Cancer Therapeutics: The Next Generation. Cancer Discov 2021;11:1626-35. [PMID: 33795234 DOI: 10.1158/2159-8290.CD-20-1503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
419 Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 2021. [PMID: 34285417 DOI: 10.1038/s41571-021-00532-x] [Reference Citation Analysis]
420 Claussen C, Rody A, Hanker L. Treatment of Recurrent Epithelial Ovarian Cancer. Geburtshilfe Frauenheilkd 2020;80:1195-204. [PMID: 33293727 DOI: 10.1055/a-1128-0280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I. MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. Genes (Basel) 2021;12:742. [PMID: 34069138 DOI: 10.3390/genes12050742] [Reference Citation Analysis]
422 Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med 2019;11:e9982. [PMID: 31273933 DOI: 10.15252/emmm.201809982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
423 Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 2019;10:2556. [PMID: 31186408 DOI: 10.1038/s41467-019-10460-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 26.5] [Reference Citation Analysis]
424 Falzone L, Scandurra G, Lombardo V, Gattuso G, Lavoro A, Distefano AB, Scibilia G, Scollo P. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). Int J Oncol 2021;59:53. [PMID: 34132354 DOI: 10.3892/ijo.2021.5233] [Reference Citation Analysis]
425 Kim M, Suh DH, Lee KH, Eom KY, Lee JY, Lee YY, Hansen HF, Mirza MR, Kim JW. Major clinical research advances in gynecologic cancer in 2019. J Gynecol Oncol 2020;31:e48. [PMID: 32319232 DOI: 10.3802/jgo.2020.31.e48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
426 Dockery LE, Gunderson CC, Moore KN. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther 2017;10:3029-37. [PMID: 28790837 DOI: 10.2147/OTT.S114714] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 8.3] [Reference Citation Analysis]
427 Laird J, Lok BH, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier JT, Rudin CM. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. J Thorac Oncol 2019;14:1743-52. [PMID: 31195178 DOI: 10.1016/j.jtho.2019.05.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
428 Monteiro AN, Bouwman P, Kousholt AN, Eccles DM, Millot GA, Masson JY, Schmidt MK, Sharan SK, Scully R, Wiesmüller L, Couch F, Vreeswijk MPG. Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. J Med Genet 2020;57:509-18. [PMID: 32152249 DOI: 10.1136/jmedgenet-2019-106368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
429 Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann Surg Oncol 2020;27:1780-7. [PMID: 32285271 DOI: 10.1245/s10434-020-08322-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
430 Sun C, Cao W, Qiu C, Li C, Dongol S, Zhang Z, Dong R, Song K, Yang X, Zhang Q, Kong B. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. J Hematol Oncol 2020;13:9. [PMID: 32005272 DOI: 10.1186/s13045-020-0844-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
431 Lu J, Zhang W, Ding Y, Li X, Song J. Expression of miR-26b in ovarian carcinoma tissues and its correlation with clinicopathology. Oncol Lett 2019;17:4417-22. [PMID: 30944634 DOI: 10.3892/ol.2019.10117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
432 Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci 2016;17:E2113. [PMID: 27983698 DOI: 10.3390/ijms17122113] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 15.2] [Reference Citation Analysis]
433 Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019;5:393-401. [PMID: 30676622 DOI: 10.1001/jamaoncol.2018.6258] [Cited by in Crossref: 138] [Cited by in F6Publishing: 113] [Article Influence: 69.0] [Reference Citation Analysis]
434 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20:e15-28. [PMID: 30614472 DOI: 10.1016/S1470-2045(18)30786-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 37] [Article Influence: 87.0] [Reference Citation Analysis]
435 McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. J Med Genet 2018;55:571-7. [PMID: 30042185 DOI: 10.1136/jmedgenet-2018-105472] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
436 Sahin ID, Jönsson JM, Hedenfalk I. Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. Oncotarget 2019;10:6981-96. [PMID: 31857852 DOI: 10.18632/oncotarget.27363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
437 Ni J, Cheng X, Chen J, Guo W, Dai Z. Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety. Onco Targets Ther 2020;13:9857-63. [PMID: 33116571 DOI: 10.2147/OTT.S268613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
438 Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 2020;5:60. [PMID: 32355263 DOI: 10.1038/s41392-020-0150-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 60.0] [Reference Citation Analysis]
439 Pearre DC, Tewari KS. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Ther Clin Risk Manag 2018;14:2189-201. [PMID: 30464492 DOI: 10.2147/TCRM.S149248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
440 Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem 2019;461:37-46. [PMID: 31292831 DOI: 10.1007/s11010-019-03586-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
441 da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo) 2018;73:e450s. [PMID: 30133561 DOI: 10.6061/clinics/2018/e450s] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
442 Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R. An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. Cancers (Basel) 2021;13:3113. [PMID: 34206535 DOI: 10.3390/cancers13133113] [Reference Citation Analysis]
443 Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, Schneider S, du Bois A, Harter P. Low-grade Serous Ovarian Carcinoma. Geburtshilfe Frauenheilkd 2018;78:972-6. [PMID: 30364401 DOI: 10.1055/a-0717-5411] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
444 van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, Mathijssen RHJ, Danser AHJ, Lang NN. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res 2021;128:1040-61. [PMID: 33793337 DOI: 10.1161/CIRCRESAHA.121.318051] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
445 Pellegrino B, Mateo J, Serra V, Balmaña J. Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? ESMO Open 2019;4:e000480. [PMID: 31231558 DOI: 10.1136/esmoopen-2018-000480] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
446 Min A, Lee KH, Im SA. DNA Damage Repair Inhibitor for Breast Cancer Treatment. Adv Exp Med Biol 2021;1187:159-79. [PMID: 33983578 DOI: 10.1007/978-981-32-9620-6_8] [Reference Citation Analysis]
447 Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. J Clin Oncol 2021;39:2594-604. [PMID: 34019431 DOI: 10.1200/JCO.21.00605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
448 Peyraud F, Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers (Basel) 2020;12:E1502. [PMID: 32526888 DOI: 10.3390/cancers12061502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 31.0] [Reference Citation Analysis]
449 Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Obstet Gynecol 2019;133:795-802. [PMID: 30870286 DOI: 10.1097/AOG.0000000000003171] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 15.0] [Reference Citation Analysis]
450 Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020;12:E1206. [PMID: 32403357 DOI: 10.3390/cancers12051206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
451 DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. J Clin Oncol 2020;38:3528-37. [PMID: 32749942 DOI: 10.1200/JCO.20.00799] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
452 Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 2018;9:37080-96. [PMID: 30647846 DOI: 10.18632/oncotarget.26354] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
453 Principe DR, Kamath SD, Munshi HG, Mohindra NA. Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib. Oncologist 2020;25:301-5. [PMID: 32297440 DOI: 10.1634/theoncologist.2019-0393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
454 Barretina-Ginesta MP. DNA damaging agents in ovarian cancer. EJC Suppl 2020;15:67-72. [PMID: 33240444 DOI: 10.1016/j.ejcsup.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
455 Principe DR, Narbutis M, Koch R, Rana A. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. Sci Rep 2020;10:20223. [PMID: 33214570 DOI: 10.1038/s41598-020-76975-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
456 Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 2018;33:401-416.e8. [PMID: 29533782 DOI: 10.1016/j.ccell.2018.01.019] [Cited by in Crossref: 106] [Cited by in F6Publishing: 84] [Article Influence: 35.3] [Reference Citation Analysis]
457 Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol 2021;225:68.e1-68.e11. [PMID: 33549538 DOI: 10.1016/j.ajog.2021.01.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
458 Lønning PE, Eikesdal HP, Løes IM, Knappskog S. Constitutional Mosaic Epimutations - a hidden cause of cancer? Cell Stress 2019;3:118-35. [PMID: 31225507 DOI: 10.15698/cst2019.04.183] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
459 Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, Butow PN, Boyle F, Best M, Taylor N, Bell K, Tucker K. Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. Fam Cancer 2021. [PMID: 33970363 DOI: 10.1007/s10689-021-00261-1] [Reference Citation Analysis]
460 Coan M, Rampioni Vinciguerra GL, Cesaratto L, Gardenal E, Bianchet R, Dassi E, Vecchione A, Baldassarre G, Spizzo R, Nicoloso MS. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. Int J Mol Sci 2018;19:E2512. [PMID: 30149579 DOI: 10.3390/ijms19092512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
461 Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol 2020;158:16-24. [PMID: 32386911 DOI: 10.1016/j.ygyno.2020.04.694] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
462 Trillsch F, Mahner S, Czogalla B, Rottmann M, Chekerov R, Braicu EI, Oskay-Öczelik G, Wimberger P, Richter R, Sehouli J. Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. J Gynecol Oncol 2021;32:e37. [PMID: 33825355 DOI: 10.3802/jgo.2021.32.e37] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]